89bio Inc.

The sponsor concentrates its research efforts on addressing severe metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver condition characterized by inflammation and fibrosis. Their investigational approaches target patients with advanced hepatic fibrosis, particularly those at stages F2 and F3, representing significant disease burden and elevated risk of progression to cirrhosis. The research portfolio emphasizes therapeutic interventions designed to modify disease progression in patients with confirmed liver fat accumulation and metabolic dysfunction.

• Metabolic Dysfunction-Associated Steatohepatitis (MASH)
• Advanced Hepatic Fibrosis Management
• Liver Inflammation and Scarring

The therapeutic development strategy focuses on patients with documented histological evidence of disease, targeting populations with elevated liver enzyme levels and metabolic abnormalities that contribute to progressive liver damage.